Sonoma Pharmaceuticals Announces Expanded Dental Care Line with a New Product for Professional Care in the U.S. and a New Product for Professional and Consumer Care in Switzerland

Author's Avatar
Aug 19, 2021

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that it has launched two new dental products. OroGenix Oral Hygiene Rinse is Sonoma’s second dental product in the U.S., and was developed with its partner Gabriel Science, LLC. Additionally, in Switzerland, Sonoma and its partner, Medical Systems Solutions, have launched Microdacyn® Oral Care for both professional and consumer use.